Noninvasive detection of lung transplant dysfunction using breath tests
Noninvasive Early Detection of Lung Allograft Dysfunction After Lung Transplantation With Multiple Breath Washout Test: Lung Clearance Index as an Early Marker
This study is testing a breath test to see if it can help find early signs of lung transplant rejection in patients three months after their surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich) |
| Trial ID | NCT05586906 on ClinicalTrials.gov |
What this trial studies
This study aims to detect chronic rejection, known as bronchiolitis obliterans syndrome (BOS), in lung transplant recipients through a noninvasive method called Multiple Breath Washout (MBW) tests. By measuring lung clearance index (LCI) three months post-transplant, the study seeks to identify early signs of BOS, which is a leading cause of mortality after the first year of transplantation. Early detection may allow for timely treatment adjustments to improve patient outcomes. Approximately 90 participants from Zurich University Hospital will be involved in this assessment.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who have undergone bilateral lung transplantation at Zurich University Hospital.
Not a fit: Patients who have undergone retransplantation will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier interventions that significantly improve survival rates for lung transplant recipients.
How similar studies have performed: Other studies have shown promise in using noninvasive methods for early detection of transplant dysfunction, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All recipients who underwent bilateral lung transplantation at Zurich University Hospital will be included. Exclusion Criteria: * Retransplantation
Where this trial is running
Zurich
- University Hospital Zurich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Carolin Steinack, MD — University of Zurich
- Study coordinator: Carolin Steinack, MD
- Email: carolin.steinack@usz.ch
- Phone: 0041442551111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.